<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842475</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS:231300</org_study_id>
    <nct_id>NCT03842475</nct_id>
  </id_info>
  <brief_title>Who Will Benefit From Bariatric Surgery for Diabetes?</brief_title>
  <official_title>Who Will Benefit From Bariatric Surgery for Diabetes? Using Fat Distribution Measurement, Gut Hormone Profiles and Genetic Data to Predict Diabetes Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study investigating the influence of fat distribution, genetic susceptibility markers for&#xD;
      type 2 diabetes (T2DM) and fat distribution, epigenetic and transcriptomic changes and gut&#xD;
      hormone responses to a mixed meal on diabetes remission following bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">June 5, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes remission (partial or complete)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetes remission (complete)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference, waist/hip ratio (cm)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (kg/m2)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue</measure>
    <time_frame>1 year</time_frame>
    <description>Dual Energy Xray Absorptiometry measurement (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue</measure>
    <time_frame>1 year</time_frame>
    <description>Magnetic resonance imaging (MRI) measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ectopic fat</measure>
    <time_frame>1 year</time_frame>
    <description>MRI measurement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in epigenetic data in tissues.</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the transcriptome in tissues</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gut hormone profiles</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Histological scoring of specimens for Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in gut microbiome</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Surgical cohort</arm_group_label>
    <description>Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy volunteers with normal body mass index</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass (RYGB)</intervention_name>
    <description>Bariatric surgery</description>
    <arm_group_label>Surgical cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 150 patients recruited to completion from Imperial Weight Centre. Up to 60 healthy&#xD;
        volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Bariatric surgery group&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females planning to undergo RYGB&#xD;
&#xD;
          -  18-80 years&#xD;
&#xD;
          -  Type 2 diabetes mellitus or prediabetes&#xD;
&#xD;
          -  Stable weight for at least 3 months&#xD;
&#xD;
          -  Obese (BMI ≥30kg/m2)&#xD;
&#xD;
          -  Eligible for surgery on the National Health Service (NHS) under The National Institute&#xD;
             for Health and Care Excellence (NICE) 2014 criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Low fasting C-peptide&#xD;
&#xD;
          -  Secondary diabetes or absence of β-cell function&#xD;
&#xD;
          -  Unable to undergo DEXA, cirrhosis, ascites, or other condition that may modify body&#xD;
             fat composition e.g. underlying malignancy&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Participation in another (interventional) trial within the last 3 months&#xD;
&#xD;
          -  Unable to understand English&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Aged 18-80 years&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Body mass index 19 - 25 kg/m2&#xD;
&#xD;
          -  Stable weight for at least three months&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Abnormal glucose tolerance and fasting glucose&#xD;
&#xD;
          -  History of any medical, or other condition, or use of any medications, including&#xD;
             over-the-counter products, which, in the opinion of the investigators, would either&#xD;
             interfere with the study&#xD;
&#xD;
          -  Without access at home to a telephone, or other factor likely to interfere with&#xD;
             ability to participate reliably in the study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Unable to maintain adequate contraception for the duration of the study&#xD;
&#xD;
          -  Donated blood during the preceding 3 months or intention to do so before the end of&#xD;
             the study&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Participation in another trial within the last 3 months&#xD;
&#xD;
          -  Unable to understand English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tricia Tan, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia S Kenkre, MB BChir</last_name>
    <phone>+44208383242</phone>
    <email>imperial.bariatricstudy@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia S Kenkre, MB BChir</last_name>
    </contact>
    <investigator>
      <last_name>Tricia Tan, MB ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

